Test 2: Wk7: 6 Water Balance - Puri Flashcards
— and — consumption decide solute excretion
salt and protein
— controls water excretion
hydration
if free water clearance is negative the kidney is
conserving water
CH2O =
CH2O = V (1 - (Uosm / Posm)
max and min free water clearance
1200 mOm/L
50 mOm/L
function of the countercurrent mechanism
create urine with an osmolarity different from serum osmolarity
countercurrent mechanism conserve water
generates urine osmolarity greater than plasma
countercurrent mechanism excrete water
urine osmolarity less than plasma
concentrated urine is produced when — is present in the plasma
ADH
In the absence of — a dilute urine is produced.
ADH
— is impermeable to solutes, but freely permeable to water.
The descending limb
— reabsorbs large quantities of NaCl & is impermeable to water.
The ascending limb
Reabsorption of NaCl without water creates a
dilute urine
— is called the “diluting segment”
The thick ascending limb
The interstitial around Henle’s loop provides the ΔOsm for
water to cross compartments
The medullary interstitium in the juxtaglomerular nephrons is —, with — increasing towards the hairpin loop
hypertonic; tonicity
— & — are required for renal water conservation
Hypertonic medullary interstitium and ADH
Medullary Hypertonicity does what
draws water out
ADH Provides
water permeability
Urine is progressively diluted by the —, —, and — regardless of the state of hydration
tALH, TAL, DCT—
urine at the end of the proximal tubule is always
isotonic
— and — are impermeable to water
tALH and TAL
Medullary Hypertonicity is Made By (3)
- Thin ascending limb—passive transport
2.Thick ascending limb—NKCC2
3.Collecting duct—urea transport by UTA1
—stimulated by ADH
Urine osmolality — and then —
along the nephron
rises; falls
Na transport in TAL
active
The Presence of Urea draws water out of the —, concentrating urine with NaCl.
tDLH
urea recycling
Urea that diffuses out of the MCD re-enters
the tubules in the thin limbs
ADH and urea
ADH responsible for removing urea
if free water clearance is negative then Na excretion > < =water excretion
>
If urinary osmolality is greater than
plasma—free water clearance is said to be
negative
If urinary osmolality is less than plasma —free water clearance is said to be
positve
ADH (AVP) binds to, and activates, —on the — of the nephrons and increases —
This leads to
V2 receptor; collecting ducts; cAMP
recycling of AQP2 & UT-A1 to
the luminal membrane
Through V1 receptor AVP induces
vasoconstriction and platelet aggregation
Normal control of ADH Secretion is via the
osmoreceptors
Osmoreceptors normally control
urine water excretion
In response to heart failure or hypovolemic shock the kidney — NaCl and water
conserves
ADH increases water permeability of — nephron segments after distal convoluted tubule —action of —receptors
ALL, V2
Primary effect of ADH increase
increase of AQP2 channels into the cell membrane
Additional effects of ADH increase
increase ins NKCC2 activity in TAL
Increase urea permeability in collecting duct
two key stimulators of ADH release
↑Plasma osmolarity and ↓intravascular volume
if urine osmolarity > plasma osmolarity,
CH2O is NEGATIVE—
urine is concentrated
if urine osmolarity < plasma osmolarity,
CH2O is POSITIVE
if urine osmolarity ≈ plasma osmolarity
CH2O is zero (seen with
loop diuretics)
Too little ADH activity
Leads to excessive water loss in urine, excessive urine volume of dilute
urine and increase in plasma sodium – Diabetes Insipidus
Too much ADH activity
Leads to too much water reabsorption, hyponatremia and potential
hypervolemia – patients with brain injuries (SIADH) and patients on loop diuretics
Central diabetes insipidus
inability of the neurohypophysis to release AVP in response to osmolality increases
very low or unmeasurable levels of serum AVP, too low for Posm
Nephrogenic diabetes insipidus
caused by the inability of an otherwise normal kidney to respond to AVP
elevated serum AVP
Gestational diabetes insipidus
elevated levels or activity of placental vasopressinase during pregnancy
very low or unmeasurable levels of serum AVP
Primary polydipsia
disorder of excess fluid ingestion rather than of vasopressin secretion or activity—usually psychogenic
very low or unmeasurable levels of serum
AVP, but appropriate to low Posm
Osmoreceptor dysfunction
polyuria, but no polydipsia—very low or unmeasurable levels of serum AVP—Only DI with hypernatremia
Diabetes Insipidus Central is
Idiopathic
Diabetes Insipidus Central Genetic defect
Dominant (AVP gene mutation)
Recessive (DIDMOAD syndrome
Recessive DIDMOAD syndrome
association of diabetes insipidus with diabetes mellitus, optic atrophy,
deafness
Diabetes Insipidus 2 types
central and nephrogenic
Diabetes Insipidus Nephrogenic genetic defect (2)
V2 receptor mutation
Aquaporin-2 mutation
Diabetes Insipidus Nephrogenic Drug therapy
- Lithium
- Demeclocycline Poisoning
- Heavy metals
Diabetes Insipidus Nephrogenic associated with
Chronic kidney disease
Diabetes Insipidus Symptoms
Large volumes 3.5-20 L/d of dilute urine are produced
Blood volume↓, while [Na+]↑ and osmolality↑
extreme thirst, and polydipsia
most Diabetes Insipidus patients are not
hypernatremic
Central Diabetes Insipidus tx
Hormone replacement
Central Diabetes Insipidus Hormone replacement (2)
Vasopressin - not used
DESMOPRESSIN
Nephrogenic Diabetes Insipidus Results from
Genetic defects in ADH receptor (X-linked) or aquaporin-2 (Autosomal)
drug side effect
Nephrogenic Diabetes Insipidus tx
both types of diabetes insipidus can be treated with thiazide diuretics
Nephrogenic Diabetes Insipidus response to DDAVP
does not respond
Convaptan action
V1A and V2 Antagonist
Convaptan lowers blood volume,
only use in — and — patients
euvolemic and hypervolemic
Convaptan administration
Continuous IV infusion for maximum of 4 days, hence only used in hospitalized patients
Tolvaptan action
Selective V2 antagonist
Tolvaptan administration
oral tablets
Tolvaptan indication
tx of hyponatremia
Since Tolvaptan can produce hypovolemia/dehydration, only use in — and
— patients
euvolemic and hypervolemic
Tolvaptan only use if pts are
symptomatic
Tolvaptan for pts with
SIADH and CHF
Tolvaptan can produce
liver toxicity so therapy limited to 30 days
Tolvaptan can produce
liver toxicity so therapy limited to 30 days
Lithium Carbonate use
off label use tx of hyponatremia
SIADH
Lithium Carbonate indications
Antimanic drug
Significant toxicity if [Li+]plasma > 1mM
Lithium Carbonate side effects
30% patients→ diabetes insipidus
Renal handling analogous to sodium Re-absorbed by CD cells via Na+ channels
Lithium Carbonate side effects tx
thiazides, but lower Li+ dose, as reuptake in PT↑
Tetracycline antibiotic with unique property
Demeclocycline
Demeclocycline side effect
Diabetes insipidus, mechanism same as Li+
Demeclocycline use (4)
off-label use for tx of hyponatremia
SIADH
Heart failure
liver disease
Demeclocycline is
Less toxic and effects more predictable than Li+